Tirzepatide added to ixekizumab for psoriasis and weight issues
Treatments studied
Part of Hormones & metabolism, Skin clinical trials.
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe plaque psoriasis diagnosed by a doctor.
- Your body mass index (BMI) is 30 or higher, or 27 to 29.9 with a weight-related condition like high blood pressure or type 2 diabetes.
- You have been taking ixekizumab for about 3 months (between 2 and 4 months) before starting tirzepatide.
- You are able to start tirzepatide within 30 days of your doctor's decision.
- You have not taken tirzepatide or similar drugs (like dulaglutide, liraglutide, or semaglutide) before.
- You do not have type 1 diabetes, certain thyroid conditions, or serious stomach problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding tirzepatide (a once-weekly injection for weight and diabetes) to your current treatment with ixekizumab for psoriatic arthritis. It may help with both joint symptoms and weight.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
This trial tests if tirzepatide, a weekly injection, can help people with type 1 diabetes who are also overweight or obese. The goal is to see if it improves blood sugar control and supports weight loss.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.